[PDF][PDF] c-Myb regulates the T-bet-dependent differentiation program in B cells to coordinate antibody responses

D Piovesan, J Tempany, A Di Pietro, I Baas, C Yiannis… - Cell reports, 2017 - cell.com
Humoral immune responses are tailored to the invading pathogen through regulation of key
transcription factors and their networks. This is critical to establishing effective antibody-…

Epidemiology of venous thrombosis in children with cancer

D Piovesan, C Attard, P Monagle… - Thrombosis and …, 2014 - thieme-connect.com
There has been an extensive body of research focusing on the epidemiology of thrombosis
in adult cancer populations; however, there is significantly less knowledge about thrombosis …

Targeting CD73 with AB680 (quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity

D Piovesan, JBL Tan, A Becker, J Banuelos… - Molecular Cancer …, 2022 - AACR
T cells play a critical role in the control of cancer. The development of immune checkpoint
blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer …

[PDF][PDF] KDM6B-dependent chromatin remodeling underpins effective virus-specific CD8+ T cell differentiation

…, JE Prier, XYX Sng, MLT Nguyen, D Piovesan… - Cell reports, 2021 - cell.com
Naive CD8 + T cell activation results in an autonomous program of cellular proliferation and
differentiation. However, the mechanisms that underpin this process are unclear. Here, we …

Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells

D Piovesan, AE de Groot, S Cho, AE Anderson… - Cancer Research, 2024 - AACR
TIGIT is an inhibitory receptor on immune cells that outcompetes an activating receptor,
CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT and CD226 on …

Safety and efficacy outcomes of home and hospital warfarin management within a pediatric anticoagulation clinic

S Jones, S McLoughlin, D Piovesan… - Journal of Pediatric …, 2016 - journals.lww.com
The complexity of managing children with chronic disease has led to an increase in the use
of long-term warfarin therapy. Time in therapeutic range (TTR) is the preferred method for …

Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control

MJ Walters, D Piovesan, J Tan, D DiRenzo, F Yin… - Cancer Research, 2018 - AACR
INTRODUCTION: Extracellular adenosine triphosphate (ATP) is efficiently hydrolyzed to
adenosine by ecto-nucleotidases CD39 and CD73, which converts adenosine-monophosphate (…

Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression

D DiRenzo, D Piovesan, J Tan, DH Miles… - Cancer Immunology …, 2019 - AACR
Introduction: Adenosine, generated through the hydrolysis of extracellular adenosine
monophosphate (AMP) by the ecto-nucleotidase CD73, is an important mechanism for …

258 AB308 is an anti-TIGIT antibody that enhances immune activation and anti-tumor immunity alone and in combination with other IO therapeutic agents

D Piovesan, A Lopez, P Schweickert… - Journal for …, 2021 - search.proquest.com
Background TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor
expressed on natural killer (NK) cells, CD8 + T cells, CD4 + T cells and regulatory T cells (T …

[PDF][PDF] AB598, a Therapeutic Anti-CD39 Antibody, Elevates ATP and Increases Immunogenicity in the Tumor Microenvironment

K Parashar, J Clor, D Piovesan, C Mitchell… - Cancer Immunology …, 2022 - arcusbio.com
❖ CD39 is expressed at both the mRNA and protein level, on both primary and in vitro-derived
myeloid cell populations. ❖ Nanostring profiling confirms CD39 expression and the …